HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1490978SDGR stock profile & AI dashboard →

13F Pro Quality Score

33.0/100

Rank #2,402 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

85.5/100

Profitability

17.5/100

Balance Sheet

18.9/100

Earnings Quality

1.3/100

Free Cash Flow

9.4/100

Institutional Flow

16.4/100

Revenue Scale

27.4/100

Dilution Risk

10.8/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

SDGR Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for Schrodinger, Inc. (SDGR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SDGR at 33.0/100 on a 32-signal composite quality model, placing it at rank #2,402 of 2,960 stocks — the bottom half of the AI-ranked universe. SDGR scores in the top quartile across revenue growth (85.5). Areas of concern include earnings quality (1.3) and free cash flow (9.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Schrodinger, Inc. reports quarterly revenue of $58.9M, net income of $6.0M, an operating margin of -70.5%. Top institutional holders of SDGR by reported 13-F value include BlackRock, GATES FOUNDATION, Rubric Capital Management, based on the most recent SEC filings. SDGR trades on the Nasdaq exchange and files with the SEC under CIK 1490978. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SDGR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Schrodinger, Inc. directly from SEC EDGAR. Schrodinger, Inc.'s 13F Pro composite quality score has ranged between 22 and 55 since 2021, currently 33.0 — a declining long-term trajectory across 69 quarterly and live scoring snapshots.

Fun facts about Schrodinger, Inc.

Quirks, history, and lore behind SDGR — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. life-sciences software company · listed on Nasdaq · applies computational chemistry and physics-based simulation to drug discovery.
  • 2
    The Numbers
    Annual revenue in the range of $150–200 million — small-cap territory — with a cloud-hosted software platform that serves most of the world's top pharmaceutical companies.
  • 3
    The History
    Founded in 2010 as a spinout of technology originally developed at academia, it went public in 2020 during the biotech IPO boom and quickly became a darling of the AI-in-drug-discovery narrative.
  • 4
    The Secret
    The company doesn't just sell software — it also co-discovers drugs itself, taking milestone payments and royalties if a molecule it helped design ever reaches patients.
  • 5
    The Lore
    Its platform is named LiveDesign, and its molecular simulation engine is so computationally intense it was an early showcase customer for GPU-accelerated cloud computing.
  • 6
    The Giveaway
    Named after the physicist famous for a thought experiment involving a cat that is simultaneously alive and dead — which, coincidentally, is also how investors feel about its stock.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$58.9M

Net Income

Q2 2026

$6.0M

Free Cash Flow

Q2 2026

$-34.4M

Operating Margin

Q2 2026

-70.5%

ROIC

Q2 2026

-50.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+23.3% YoY
$255.9MFY 2025
FY22 $181.0MFY23 $216.7MFY24 $207.5MFY25 $255.9M

Net Income

+44.8% YoY
$-103.3MFY 2025
FY22 $-149.2MFY23 $40.7MFY24 $-187.1MFY25 $-103.3M

Operating Income

+20.3% YoY
$-166.9MFY 2025
FY22 $-146.8MFY23 $-177.4MFY24 $-209.3MFY25 $-166.9M

EPS (Diluted)

+45.1% YoY
$-1.41FY 2025
FY22 $-2.10FY23 $0.54FY24 $-2.57FY25 $-1.41

Total Assets

-11.8% YoY
$726.2MFY 2025
FY22 $688.6MFY23 $803.0MFY24 $823.2MFY25 $726.2M

Op. Cash Flow

+108.8% YoY
$13.9MFY 2025
FY22 $-119.7MFY23 $-136.7MFY24 $-157.4MFY25 $13.9M

Free Cash Flow

+107.6% YoY
$12.5MFY 2025
FY22 $-127.7MFY23 $-150.1MFY24 $-164.7MFY25 $12.5M

Get alerted when SDGR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Schrodinger, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Companies Similar to SDGR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TWST

Twist Bioscience Corp

34
AI score
Similar quality profile · 9 shared holders
WGS

GeneDx Holdings Corp.

35
AI score
Similar quality profile · 9 shared holders
GH

Guardant Health, Inc.

39
AI score
Similar quality profile · 7 shared holders
ESTA

ESTABLISHMENT LABS HOLDINGS INC.

34
AI score
Similar quality profile · 5 shared holders
NPCE

NeuroPace Inc

31
AI score
Similar quality profile · 3 shared holders
SPRY

ARS Pharmaceuticals, Inc.

24
AI score
Similar quality profile · 6 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put SDGR on your watchlist

Track score changes the day Schrodinger, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is SDGR a good stock to buy?

13F Pro's AI-powered analysis of Schrodinger, Inc. (SDGR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SDGR are available on the SDGR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SDGR is classified as a small company.

Which hedge funds own SDGR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SDGR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Schrodinger, Inc.'s investment landscape.